JEFHCLON16: Growth Strategies And What's In Store Post-US Election
• By Tina Tan
The Jefferies 2016 London Healthcare Conference, the largest health-care-dedicated investor meeting in Europe, took place this week in London. More than 140 pharma, biotech and medtech companies formally presented, and many more attended to meet and connect with investors and potential commercial partners. This article rounds up the best Tweets posted by the Medtech Insight team attending #JEFHCLON16. It includes insights from a panel session on what's in store for health care in the US post-election, as well as company updates from LivaNova, Smith & Nephew, Coloplast, Varian Medical Systems and bioMérieux.
The 2016 Jefferies London Healthcare Conference, now in its seventh year, looks to be the biggest yet, with more than 140 companies across the health-care sector presenting, and many more delegates attending for one-on-one meetings with potential investors and partners.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
OneCell Diagnostics, the Mumbai-based startup backed with $16m in series A funding, is rebranding to 1Cell.Ai to represent the firm's focus on combining deep science with AI-powered capabilities.
Abbott and J&J reassured investors they will maintain their 2025 profit forecasts. Abbott projects $5.05 to $5.25 per share and plans a new $500m investment in manufacturing and R&D sites. J&J anticipates $400m in tariff-related costs but committed $55bn in US investment over four years.
As it celebrates 75 years shaping the medtech industry, Medtronic invited Medtech Insight to its Minneapolis headquarters to get a closer look at the company’s past, what it’s working on now, and what’s on the horizon.
According to a survey of health care professionals by J&J, over 45% of surveyed respondents reported experiencing symptoms of burnout, including emotional exhaustion and reduced sense of personal accomplishment. This affects not just clinicians, but also the quality and safety of care they deliver. Most clinicians (72%) say that data and technology could significantly help alleviate this burden.
Abbott and J&J reassured investors they will maintain their 2025 profit forecasts. Abbott projects $5.05 to $5.25 per share and plans a new $500m investment in manufacturing and R&D sites. J&J anticipates $400m in tariff-related costs but committed $55bn in US investment over four years.
Congress has launched an inquiry into 23andMe amid privacy concerns following its bankruptcy, particularly regarding the potential sale of sensitive user data. Additionally, a Cybernews report gave 40 DNA testing firms an average cybersecurity grade of D, citing widespread vulnerabilities and data breaches, along with inadequate public information about their security practices.
